Abstract

In order to improve therapeutic compliance and prevent antimalarial drug resistance, we conducted this study to evaluate the knowledge of physicians and pharmacists in Kayes on the management of adverse effects of antimalarial drugs. Methods: A cross-sectional study was conducted from July to November 2017 among physicians and pharmacists selected by simple random sampling and practicing in the Kayes region for more than one year. The survey was based on a questionnaire proposed by the national pharmacovigilance center. In addition to a descriptive analysis of the results, a logistic regression analysis was performed to assess potential factors that could be associated with knowledge. Results: Among 151 physicians and pharmacists participated in the study, less than 40% had better knowledge about the management of antimalarial drug adverse events. Physicians and pharmacists working in government facilities were more likely to have better knowledge compared with those working in other facilities (OR=8.38; 95% CI: 2.48-28.30). In addition, pharmacists were more likely to have better knowledge than physicians (OR=3.48; 95% CI: 1.21-12.19). Conclusions: The frequency of good knowledge of the management of adverse drug reactions to antimalarials is insufficient, although membership in government structures and profession seem likely to improve it.

Highlights

  • Despite the intensification of malaria control activities through the Roll Back Malaria initiative [1], progress in malaria incidence and deaths in Africa has slowed, mainly due to stagnation in several countries with moderate or high transmission [2].Early diagnosis and prompt treatment with an effective antimalarial drug remain the priority strategy recommended by the World Health Organization (WHO)

  • Diagnosis and prompt treatment with an effective antimalarial drug remain the priority strategy recommended by the World Health Organization (WHO)

  • It is based on the use of artemisinin-based combination therapy (ACT) including artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) for the treatment of uncomplicated malaria [3]; and the use of artesunate or quinine dihydrochloride for severe malaria [4]

Read more

Summary

Introduction

Diagnosis and prompt treatment with an effective antimalarial drug remain the priority strategy recommended by the World Health Organization (WHO) It is based on the use of artemisinin-based combination therapy (ACT) including artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) for the treatment of uncomplicated malaria [3]; and the use of artesunate or quinine dihydrochloride for severe malaria [4]. These antimalarials are much safer [5], data on the safety profile of their long-term use in the general population of sub-Saharan Africa remain scarce outside of clinical trials. Post-marketing safety is likely to improve adherence to treatment and prevent antimalarial drug resistance [5,13,14]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call